Clinical Trial Update: Sunitinib in Treating Patients With Relapsed Multiple Myeloma [Phase 2]

View source ↗

Summary

This is a Phase 2 trial of sunitinib in relapsed multiple myeloma (Stage I–III). The study has completed and results were posted in March 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2013-03-06